Hisashi Ishida

Hisashi Ishida

Auto-generated profile, based on publicly available information

Hisashi Ishida

Department of Pediatrics, Okayama University Hospital, Okayama, Japan

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JCJoana Carrelha
Joana Carrelha
SMStefania Mazzi
Stefania Mazzi
AWAxel Winroth
Axel Winroth
MHMichael Hagemann-Jensen
Michael Hagemann-Jensen
CZChristoph Ziegenhain
Christoph Ziegenhain
SJSten Eirik W. Jacobsen
Sten Eirik W. Jacobsen
Rare multipotent stem cells replenish millions of blood cells per second through a time-consuming process, passing through multiple stages of increasingly lineage-restricted progenitors. Although insults to the blood-forming system highlight the need for more rapid blood replenishment from stem cells, established models of hematopoiesis implicate only one mandatory differentiation pathway for each blood cell lineage. Here, we establish a nonhierarchical relationship between distinct stem cells that replenish all blood cell lineages and stem cells that replenish almost exclusively platelets, a lineage essential for hemostasis and with important roles in both the innate and adaptive immune systems. These distinct stem cells use cellularly, molecularly and functionally separate pathways for the replenishment of molecularly distinct megakaryocyte-restricted progenitors: a slower steady-state multipotent pathway and a fast-track emergency-activated platelet-restricted pathway. These findings provide a framework for enhancing platelet replenishment in settings in which slow recovery of platelets remains a major clinical challenge.

7 August 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MYMasanori Yoshida
Masanori Yoshida
KTKanako Tanase‐Nakao
Kanako Tanase‐Nakao
HSHirohito Shima
Hirohito Shima
RSRyota Shirai
Ryota Shirai
KYKaoru Yoshida
Kaoru Yoshida
MKMotohiro Kato
Motohiro Kato

23 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Joe HaseiJoe Hasei
Joe Hasei
HIHisashi Ishida
Hisashi Ishida
HKHideki Katayama
Hideki Katayama
NMNaoko Maeda
Naoko Maeda
ANAkihito Nagano
Akihito Nagano
TOToshifumi Ozaki
Toshifumi Ozaki
This study investigated the potential of the metaverse in providing psychological support for pediatric and AYA cancer patients, with a focus on those with rare cancers. The research involved ten cancer patients and survivors from four distinct regions in Japan, who participated in metaverse sessions using customizable avatars, facilitating interactions across geographical and temporal barriers. Surveys and qualitative feedback were collected to assess the psychosocial impact of the intervention. The results demonstrated that the metaverse enabled patients to connect with peers, share experiences, and receive emotional support. The anonymity provided by avatars helped reduce appearance-related anxiety and stigma associated with cancer treatment. A case study of a 19-year-old male with spinal Ewing’s sarcoma highlighted the profound emotional relief fostered by metaverse interactions. The findings suggest that integrating virtual spaces into healthcare models can effectively address the unique needs of pediatric and AYA cancer patients, offering a transformative approach to delivering psychosocial support and fostering a global patient community. This innovative intervention has the potential to revolutionize patient care in the digital age.

25 October 1999 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
NYNobukazu Yuki
Nobukazu Yuki
MKMichio Kato
Michio Kato
MMManabu Masuzawa
Manabu Masuzawa
HIHisashi Ishida
Hisashi Ishida
TITakashi Inoue
Takashi Inoue
MHMasatsugu Hori
Masatsugu Hori

9 March 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
HIHisashi Ishida
Hisashi Ishida
TIToshihiko Imamura
Toshihiko Imamura
YTYasuhisa Tatebe
Yasuhisa Tatebe
TITakashi Ishihara
Takashi Ishihara
KSKimiyoshi Sakaguchi
Kimiyoshi Sakaguchi
KHKeizo Horibe
Keizo Horibe

27 June 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
HIHisashi Ishida
Hisashi Ishida
YMYuji Miyajima
Yuji Miyajima
NHNobuyuki Hyakuna
Nobuyuki Hyakuna
SHSatoru Hamada
Satoru Hamada
TSTakeo Sarashina
Takeo Sarashina
L(Leukemia/Lymphoma Committee of the Japanese Society of Pediatric Hematology Oncology (JSPHO)
Leukemia/Lymphoma Committee of the Japanese Society of Pediatric Hematology Oncology (JSPHO)
Background Philadelphia‐negative (Ph‐negative) myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are exceptionally rare during childhood. Thus, clinical features of pediatric Ph‐negative MPNs remain largely unknown. This study was therefore performed to address this. Methods We performed a retrospective study to collect clinical information of children diagnosed with Ph‐negative MPNs from 2000 to 2016 using questionnaires in qualified institutions in Japan. The results obtained from the questionnaire survey were then combined with those from the national registry data. Results Among 50 children identified, five had PV, 44 had ET, and one had PMF. Median age at diagnosis was 14.0, 9.0, and 0 years, respectively. Male to female ratio was 4:1, 21:23, and 1:0, respectively. Detection rates of the JAK2 V617F variant were 0/5 in PV and 9/39 in ET. Frequencies of complications, such as thrombosis and subsequent leukemia, were lower than complication frequencies in adults. We identified two children who developed subsequent leukemia, which has not been reported previously, and one of them died. Conclusion This is the first nationally representative survey of pediatric Ph‐negative MPNs. Given its rarity, an international collaboration with comprehensive genetic analyses might be needed to fully elucidate the clinical and genetic features.